Literature DB >> 22998582

Improving international research with clinical specimens: 5 achievable objectives.

Joshua LaBaer1.   

Abstract

Our increased interest in translational research has created a large demand for blood, tissue, and other clinical samples, which find use in a broad variety of research including genomics, proteomics, and metabolomics. Hundreds of millions of dollars have been invested internationally on the collection, storage, and distribution of samples. Nevertheless, many researchers complain in frustration about their inability to obtain relevant and/or useful samples for their research. Lack of access to samples, poor condition of samples, and unavailability of appropriate control samples have slowed our progress in the study of diseases and biomarkers. In this perspective, I focus on five major challenges that thwart clinical sample use for translational research and propose near term objectives to address them. They include: (1) defining our biobanking needs; (2) increasing the use of and access to standard operating procedures; (3) mapping interobserver differences for use in normalizing diagnoses; (4) identifying natural internal protein controls; and (5) redefining the clinical sample paradigm by building partnerships with the public. In each case, I believe that we have the tools at hand required to achieve the objective within 5 years. Potential paths to achieve these objectives are explored. However we solve these problems, the future of proteomics depends on access to high quality clinical samples, collected under standardized conditions, accurately annotated and shared under conditions that promote the research we need to do.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998582      PMCID: PMC3640360          DOI: 10.1021/pr300796m

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  21 in total

1.  Reduction of preanalytical variability in specimen procurement for molecular profiling.

Authors:  Virginia Espina; Claudius Mueller
Journal:  Methods Mol Biol       Date:  2012

2.  Research ethics: Treat donors as partners in biobank research.

Authors:  Krishanu Saha; J Benjamin Hurlbut
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  Standard preanalytical coding for biospecimens: defining the sample PREanalytical code.

Authors:  Fotini Betsou; Sylvain Lehmann; Garry Ashton; Michael Barnes; Erica E Benson; Domenico Coppola; Yvonne DeSouza; James Eliason; Barbara Glazer; Fiorella Guadagni; Keith Harding; David J Horsfall; Cynthia Kleeberger; Umberto Nanni; Anil Prasad; Kathi Shea; Amy Skubitz; Stella Somiari; Elaine Gunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

4.  Changing perspectives in biobank research: from individual rights to concerns about public health regarding the return of results.

Authors:  Joanna Stjernschantz Forsberg; Mats G Hansson; Stefan Eriksson
Journal:  Eur J Hum Genet       Date:  2009-05-27       Impact factor: 4.246

5.  An NCI perspective on creating sustainable biospecimen resources.

Authors:  Jimmie Vaught; Joyce Rogers; Kimberly Myers; Mark David Lim; Nicole Lockhart; Helen Moore; Sherilyn Sawyer; Jeffrey L Furman; Carolyn Compton
Journal:  J Natl Cancer Inst Monogr       Date:  2011

Review 6.  A genecentric Human Protein Atlas for expression profiles based on antibodies.

Authors:  Lisa Berglund; Erik Björling; Per Oksvold; Linn Fagerberg; Anna Asplund; Cristina Al-Khalili Szigyarto; Anja Persson; Jenny Ottosson; Henrik Wernérus; Peter Nilsson; Emma Lundberg; Asa Sivertsson; Sanjay Navani; Kenneth Wester; Caroline Kampf; Sophia Hober; Fredrik Pontén; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2008-10       Impact factor: 5.911

7.  Public opinion about the importance of privacy in biobank research.

Authors:  David J Kaufman; Juli Murphy-Bollinger; Joan Scott; Kathy L Hudson
Journal:  Am J Hum Genet       Date:  2009-10-29       Impact factor: 11.025

8.  Sources of bias in specimens for research about molecular markers for cancer.

Authors:  David F Ransohoff; Margaret L Gourlay
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

9.  The Spanish HIV BioBank: a model of cooperative HIV research.

Authors:  Isabel García-Merino; Natividad de Las Cuevas; José Luis Jiménez; Jorge Gallego; Coral Gómez; Cristina Prieto; Ma Jesús Serramía; Raquel Lorente; Ma Angeles Muñoz-Fernández
Journal:  Retrovirology       Date:  2009-03-09       Impact factor: 4.602

10.  Impact of limited population diversity of genome-wide association studies.

Authors:  Susanne B Haga
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  13 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 2.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

Review 3.  Proteomics analysis of bodily fluids in pancreatic cancer.

Authors:  Sheng Pan; Teresa A Brentnall; Ru Chen
Journal:  Proteomics       Date:  2015-04-27       Impact factor: 3.984

Review 4.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

5.  What's in a sample? Increasing transparency in biospecimen procurement methods.

Authors:  Joshua LaBaer; Joseph F Miceli; Leonard P Freedman
Journal:  Nat Methods       Date:  2018-04-27       Impact factor: 28.547

Review 6.  A critical analysis of cancer biobank practices in relation to biospecimen quality.

Authors:  Amanda Rush; Kevin Spring; Jennifer A Byrne
Journal:  Biophys Rev       Date:  2015-10-22

7.  Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions.

Authors:  Chad R Borges; Douglas S Rehder; Sally Jensen; Matthew R Schaab; Nisha D Sherma; Hussein Yassine; Boriana Nikolova; Christian Breburda
Journal:  Mol Cell Proteomics       Date:  2014-04-15       Impact factor: 5.911

8.  Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic.

Authors:  Jennifer A Byrne; Jane E Carpenter; Candace Carter; Kathleen Phillips; Stephen Braye; Peter H Watson; Amanda Rush
Journal:  Biomark Insights       Date:  2021-06-14

9.  BioBanking as the central tool for translational medicine CTM issue 2013.

Authors:  György Marko-Varga
Journal:  Clin Transl Med       Date:  2013-02-06

10.  Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability.

Authors:  Charlotte Welinder; Göran Jönsson; Christian Ingvar; Lotta Lundgren; Håkan Olsson; Thomas Breslin; Akos Végvári; Thomas Laurell; Melinda Rezeli; Bo Jansson; Bo Baldetorp; György Marko-Varga
Journal:  Clin Transl Med       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.